DR info

Clinical trials : 44 / Drugs : 61 - (DrugBank : 23) / Drug target genes : 57 - Drug target pathways : 83

Drugs and their primary sponsors and trial info

ANA001XHCl (Syntagon) or VEXA-04 (Patheon)
   Anavex Germany GmbH
      2020   Phase 2   EUCTR2019-004345-32-GB   Australia;United Kingdom;
ANAVEX2-73
   Anavex Life Sciences Corp.
      2019   Phase 3   NCT03941444   Australia;United Kingdom;
      2019   Phase 2   NCT03758924   United States;
ANAVEX2-73 (blarcamesine)
   Anavex Germany GmbH
      2020   Phase 2   EUCTR2019-004345-32-GB   Australia;United Kingdom;
ANAVEX2-73 oral liquid
   Anavex Life Sciences Corp.
      2020   Phase 2/Phase 3   NCT04304482   Australia;Canada;
Administration of a high dose of desipramine
   Assistance Publique Hopitaux De Marseille
      2009   Phase 2   NCT00990691   France;
Administration of a low dose of desipramine
   Assistance Publique Hopitaux De Marseille
      2009   Phase 2   NCT00990691   France;
Alpha-tocotrienol quinone
   EDISON PHARMACEUTICALS INC.
      2013   -   EUCTR2012-005021-76-IT   Italy;
CBD - Oral Solution, is known as Epidyolex, and is the approved name
   GW Research Ltd
      2019   Phase 2;Phase 3   EUCTR2018-003370-27-GB   Australia;Canada;France;Italy;Spain;United Kingdom;United States;
CBD - Solution Orale, conosciuto come Epidiolex, questo è il nome approvato negli Stati Uniti
   GW RESEARCH LTD.
      2019   Phase 3   EUCTR2018-003370-27-IT   Canada;Germany;Italy;Spain;United Kingdom;United States;
CBD Oral solution, is known as Epidyolex and is the approved name in the EU
   GW Research Ltd
      2020   Phase 3   EUCTR2019-001605-24-GB   Australia;Canada;France;Italy;Spain;United Kingdom;United States;
CBD soluzione orale nota come Epidyolex e con tale nome è stato approvato in UE
   GW RESEARCH LTD.
      2020   Phase 3   EUCTR2019-001605-24-IT   Australia;Canada;Italy;Spain;United Kingdom;United States;
Cannabidiol
   GW RESEARCH LTD.
      2020   Phase 3   EUCTR2019-001605-24-IT   Australia;Canada;Italy;Spain;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-003370-27-IT   Canada;Germany;Italy;Spain;United Kingdom;United States;
Cannabidiol (CBD)
   GW Research Ltd
      2020   Phase 3   EUCTR2019-001605-24-GB   Australia;Canada;France;Italy;Spain;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-001605-24-ES   Australia;Canada;Italy;Spain;United Kingdom;United States;
      2019   Phase 2;Phase 3   EUCTR2018-003370-27-GB   Australia;Canada;France;Italy;Spain;United Kingdom;United States;
Cannabidiolo
   GW RESEARCH LTD.
      2020   Phase 3   EUCTR2019-001605-24-IT   Australia;Canada;Italy;Spain;United Kingdom;United States;
Cannabidiolo (CBD)
   GW RESEARCH LTD.
      2019   Phase 3   EUCTR2018-003370-27-IT   Canada;Germany;Italy;Spain;United Kingdom;United States;
Creatine monohydrate
   Medical University of Vienna
      2005   -   NCT01147575   Austria;
Dextromethorphan
   Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
      2004   Phase 3   NCT00069550   United States;
      1995   -   NCT00004807   -
   Hugo W. Moser Research Institute at Kennedy Krieger, Inc.
      2012   Phase 2   NCT01520363   United States;
      2004   Phase 2   NCT00593957   United States;
   Kennedy Krieger Inst. Johns Hopkins Medicine
      -   Phase 2   EUCTR2008-005571-10-NO   Norway;
Donepezil
   Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
      1995   -   NCT00004807   -
Donepezil hydrochloride
   Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
      2004   Phase 3   NCT00069550   United States;
EMD 128130
   Newron Pharmaceuticals S.p.A.
      2016   Phase 2   EUCTR2015-004448-20-GB   Australia;India;Italy;United Kingdom;United States;
EPI-743
   EDISON PHARMACEUTICALS INC.
      2013   -   EUCTR2012-005021-76-IT   Italy;
   Edison Pharmaceuticals Inc
      2013   Phase 2   NCT01822249   Italy;
Epidyolex and is the approved name in the EU
   GW Research Ltd
      2020   Phase 3   EUCTR2019-001605-24-ES   Australia;Canada;Italy;Spain;United Kingdom;United States;
Fingolimod (FTY720)
   University Hospital, Basel, Switzerland
      2013   Phase 1/Phase 2   NCT02061137   Switzerland;
GWP42003-P
   GW RESEARCH LTD.
      2020   Phase 3   EUCTR2019-001605-24-IT   Australia;Canada;Italy;Spain;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-003370-27-IT   Canada;Germany;Italy;Spain;United Kingdom;United States;
   GW Research Ltd
      2020   Phase 3   NCT04252586   Australia;Canada;Italy;Spain;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-001605-24-GB   Australia;Canada;France;Italy;Spain;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-001605-24-ES   Australia;Canada;Italy;Spain;United Kingdom;United States;
      2019   Phase 3   NCT03848832   Italy;Spain;United Kingdom;United States;
      2019   Phase 2;Phase 3   EUCTR2018-003370-27-GB   Australia;Canada;France;Italy;Spain;United Kingdom;United States;
Glatiramer Acetate
   Montefiore Medical Center
      2013   Phase 2   NCT02153723   United States;
Glatiramer Acetate (Copaxone®)
   Sheba Medical Center
      2014   Phase 1   NCT02023424   Israel;
Ketamine
   Rett Syndrome Research Trust
      2019   Phase 2   NCT03633058   United States;
Lovastatin
   Montefiore Medical Center
      2015   Phase 2   NCT02563860   United States;
NNZ-2566
   Neuren Pharmaceuticals Limited
      2016   Phase 2   NCT02715115   United States;
      2013   Phase 2   NCT01703533   United States;
Probiotic-Lactobacillus plantarum PS128
   National Taiwan University Hospital
      2017   -   NCT03259971   Taiwan;
Recombinant Human Insulin Growth Factor 1 (rhIGF-1)
   Boston Children's Hospital
      2013   Phase 2   NCT01777542   United States;
Rett-T
   Anagnostou, Evdokia, M.D.
      2019   Phase 2   NCT04041713   Canada;
RhIGF-1
   Boston Children’s Hospital
      2010   Phase 1   NCT01253317   United States;
Risperidone
   Janssen-Ortho Inc., Canada
      1999   Phase 3   NCT00261508   -
Sarizotan
   Newron Pharmaceuticals SPA
      2016   Phase 2/Phase 3   NCT02790034   Australia;India;Italy;United Kingdom;United States;
Topiramate
   Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
      1995   -   NCT00004807   -
Tridecanoic Acid
   Sheba Medical Center
      2017   Phase 2   NCT03059160   -
Triheptanoin
   Center for Rare Neurological Diseases, Norcross, GA
      2016   Phase 2   NCT02696044   United States;
Trofinetide
   ACADIA Pharmaceuticals Inc.
      2021   Phase 2/Phase 3   NCT04988867   United States;
      2020   Phase 3   NCT04776746   United States;
      2020   Phase 3   NCT04279314   United States;
      2019   Phase 3   NCT04181723   United States;